Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy (ESCAPE)

Inclusion Criteria:

• Patient aged 18 years and over followed at the Montreal Heart Institute's Anticoagulation clinic
• Warfarin treatment planned for at least 4 months after inclusion in the study
• Warfarin treatment initiated for at least 6 months
• Last 2 INRs between 1.5 and 4 if target INR is between 2 and 3
• Last 2 INRS between 2 and 4 if target INR is between 2.5 and 3.5
• Provide a signed informed consent

Exclusion Criteria:

• Patient unable to understand (spoken and written) French or English
• Patient refuses or is unable to attend the required training sessions
• Targeted INR other than 2 to 3 or 2.5 to 3.5
• Handicap or physical limitation compromising the patient's ability to initiate self-monitoring in the absence of a proxy helper
• Moderate to severe cognitive impairment or important comprehension problems
• Active neoplasm
• Concurrent chemotherapy
• Hypercoagulable conditions
• Life expectancy of less than 1 year documented in the medical chart
• Inclusion (at time of inclusion or 30 days prior to inclusion) in another research project involving a drug
• Patient anticoagulated with nicoumalone
• Pregnancy or breastfeeding
• Active bleeding (except for menses)
• Recent major bleeding (less than 3 months before inclusion)
• Stroke, acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft, cardiac valve replacement, deep veinous thrombosis or pulmonary embolism in the 3 months prior to inclusion
• Any other condition that, in the opinion of the investigators, of the treating physician or of the healthcare professionals working at the anticoagulation clinic could make self-management by the patient impossible